ILEP Members’ Assembly
Brussels, 10th October 2018

Annex: 4 – Global Partnership for Zero Leprosy roadmap, 10.10.2018

Expected outcome of session:
Update and discussions on GPZL’s roadmap
Countries and peer-to-peer mapping/assessment teams share experience in a meeting of country program officers and partners during International Leprosy Congress.

**Action Framework for Zero Leprosy**

### 2018
- **RESEARCH AGENDA WORKING GROUP**
  - Aligned Research Agenda for Zero Leprosy
  - Diagnostic tests
  - Post-exposure prophylaxis (PEP)
  - Vaccines
  - Operational research
  - Stigma and disability as barriers to zero leprosy
  - Epidemiologic modeling, investment case and other cross-cutting issues

### 2019
- **OPERATIONAL EXCELLENCE WORKING GROUP**
  - Toolkit for National Capacity Building for Zero Leprosy
  - Assessment and mapping tools to identify opportunities and gaps
  - Template for visioning and development of 5-year national plans moving towards the goal of Zero Leprosy
  - A menu of best practices, including operational and scientific, for consideration in national plans
  - Country case studies and success stories
  - Developed in partnership with WHO

- **ADVOCACY & PARTNERSHIP WORKING GROUP**
  - Global and national advocacy, partnership and resource-mobilization to develop support and funding for:
    - The use of the Toolkit’s menu of options in countries, and the necessary capacity increases to support this.
    - Research priorities and their translation into practice as components of the Toolkit.

### 2020 onward
- **New scientific tools and approaches are tested and informed by the Toolkit for National Capacity Building. Country experiences inform the research agenda.**
  - Countries apply and are funded to use the toolkit to develop and fund national capacity plans.
  - New scientific tools and approaches are added to toolkit as they are developed.
  - Countries and partners meet annually to share success stories and best practices.

### 2025 & beyond
- **Ultimate Goal**
  - Countries have measurably improved national capacity in disease surveillance, early diagnosis and treatment (including disease management). They are implementing new scientific tools and approaches. There is a measurable decrease in disability and discrimination, including laws that foster stigma.

**IN EVERY COUNTRY:**

- No disease
- No disability
- No discrimination
- No stigma

www.zeroleprosy.org